Opinion|Videos|March 4, 2024
Multidisciplinary Collaboration and Expert Insights in the Management of Advanced Prostate Cancer
Author(s)Rana R. McKay, MD, Neal Shore, MD, FACS
Our expert panel provide insightful discussion on the power of multidisciplinary expertise in advanced prostate cancer.
Advertisement
Episodes in this series
Advertisement
Related to this article
Faculty convened at an OncLive Scientific Interchange and Workshop to weigh how new regimens should reshape sequencing in prostate cancer.
Advertisement
Advertisement
Trending on OncLive
1
DESTINY-Lung04 Showcases PFS Benefit With First-Line T-DXd in HER2-Mutant NSCLC
2
Intercalated Gefitinib Plus Chemotherapy Improves DFS in Resected EGFR-Mutant NSCLC
3
Adjuvant Osimertinib Keeps OS Benefit at 8 Years in Resected EGFR-Mutated Stage IB to IIIA NSCLC
4
PAPILLON: Frontline Amivantamab Plus Chemotherapy Yields 34.3-Month Median OS in EGFR Exon 20 Insertion–Positive NSCLC
5